Recordati is acquiring Sanofi’s Enjaymo, the only approved drug for the rare blood disorder cold agglutinin disease. Achieving sales milestones could bring the deal’s value to more than $1 billion.
A rare disease drug that Sanofi added via its $11.6 billion Bioverativ acquisition is now approved for treating the blood disorder cold agglutinin disease. The regulatory nod makes the antibody drug the first approved treatment for this rare disease that leads to anemia.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
Since 2014, True North Therapeutics has raised $97 million for its unique approach to autoimmune disease. Its initial clinical work treats a rare anemia.